Clinical Trial Update: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 study update for KH903 in advanced gastric or gastroesophageal junction adenocarcinoma as second-line therapy; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• KH903

Snippet

Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Gastric Cancer, Gastroesophageal Cancer | Phase 2 | Status: UNKNOWN